BNGO
Bionano Genomics, Inc. NASDAQ Listed Aug 21, 2018$1.33
Mkt Cap $4.4M
52w Low $1.06
6.1% of range
52w High $5.50
50d MA $1.18
200d MA $1.88
P/E (TTM)
-0.2x
EV/EBITDA
-0.5x
P/B
0.1x
Debt/Equity
0.2x
ROE
-59.4%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
1.60
50d MA
$1.18
200d MA
$1.88
Avg Volume
330.6K
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
9540 Towne Centre Drive · San Diego, CA 92121 · US
Data updated apr 24, 2026 10:20pm
· Source: massive.com